

## DX- Report Form Field Safety Corrective Action

In accordance with the Medical Devices Vigilance System (MEDDEV 2.12/1 rev 6)

<b>1 Administrative information</b>	
<b>Destination</b> Name of National Competent Authority MHRA-Medicines and Healthcare Products Regulatory Agency Address of National Competent Authority <b>151 Buckingham Palace Road</b> <b>London</b> <b>SW1W 9SZ</b> <b>United Kingdom</b>	<b>Stamp box for the Competent Authority (~ 60 x 40 mm)</b>
Date of this report 21st May 2012 (Initial Report)	
Reference number assigned by the manufacturer CHC 12-01	
Incident reference number and name of the co-ordinating NCA -Competent Authority (if applicable):	
Identify to what other Competent Authorities this report was <b>also</b> sent	
<b>2 Information on submitter of the report</b>	
Status of submitter  <input type="checkbox"/> Manufacturer <input checked="" type="checkbox"/> Authorised Representative within EEA <input type="checkbox"/> Others: (identify the role):	
<b>3 Manufacturer information</b>	
Manufacturer name Siemens Healthcare Diagnostics Inc	
Manufacturer's contact person Mindy Losapio	
Address 511 Benedict Avenue	
Postal code 10591	City Tarrytown, NY
Phone +1 (914) 524-2312	Fax
E-mail Mindy.losapio@siemens.com	Country USA

## 4 Authorised Representative information

Name of the Authorised Representative

Siemens Healthcare Diagnostics Limited

The Authorised Representative's contact person

Anthony Walsh

Address

Sir William Siemens Square

Postal code

GU16 8QD

City

Frimley, Camberley

Phone

+ 44 (0) 1908 487600

Fax

+ 44 (0) 1908 487601

E-mail

Anthony.walsh@siemens.com

Country

UK

## 5 National contact point information

National contact point name

Name of the contact person

Address

Postal code

City

Phone

Fax

E-mail

Country

## 6 Medical device information

Class

AIMD Active implant

MDD Class III

IVD Annex II List A

MDD Class IIb

IVD Annex II List B

MDD Class IIa

IVD Devices for self-testing

MDD Class I

IVD General

Nomenclature system (preferable GMDN)

GMDN

Nomenclature code

33165 (ALPAMP)

33165 (ALPDEA)

Nomenclature text

Alkaline Phosphatase - Total

Commercial name/ brand name / make ADVIA Chemistry Systems Alkaline Phosphatase (ALPAMP) / ADVIA Chemistry Systems Alkaline Phosphatase (ALPDEA)
Model number N/A
Serial number(s) or lot/batch number(s) ALPAMP lot # 222982 ALPDEA lot # 222987
Software version number (if applicable) N/A
Manufacturing date/ Expiry date (if applicable) ALPAMP lot 222982 2011-07-21/2012-08-30 ALPDEA lot 222987 2011-07-22/2012-08-31
Accessories/ associated device (if applicable) N/A
Notified Body (NB) ID-number N/A
<b>7 Description of FSCA</b>
Background information and reason for the FSCA, Manufacturer advises many customers observing frequent result flags (u, U, or ////) on some ALPAMP (lot 222982) and ALPDEA (lot 222987) reagent wedges, which in some cases can impede reporting of results (see below). No QC shifts or discrepant patient results observed.
Note: “u” flag indicates Abnormal high reaction absorbance exceeding the Blank (u) limit. – results can be reported “U” flag indicates Abnormal high reaction absorbance exceeding the sample (u) limit. – results can be reported. //// flag indicates calculation error – no result is calculated. As the kit ages, the incidence of //// flags is increasing.
Description and justification of the action (corrective/preventive) All affected customers are being notified of the issue by an Urgent Field Safety Notice advising them to discard the affected kits. Product Hold initiated on 23 <sup>rd</sup> February 2012.
Advice on actions to be taken by the distributor and the user. Urgent Field Safety Notice will be issued to affected customers through the local country organizations
Attached please find <input type="checkbox"/> Field Safety Notice (FSN) in English <input type="checkbox"/> FSN in national language <input type="checkbox"/> Others (please specify) ...
Time schedule for the implementation of the different actions FSCA to be issued to Siemens country RAQS organisations on 21 <sup>st</sup> May 2012, to then be issued to affected customers in their local countries.

These countries within the EEA and Switzerland are affected by this FSCA:

- within the EEA and Switzerland:

AT  BE  BU  CH  CY  CZ  DE  DK  EE  ES  FI  FR  GB  GR  HU  IE  
 IS  IT  LI  LT  LU  LV  MT  NL  NO  PL  PT  RO  SE  SI  SK

- Candidate Countries  CR  TR

ALL EEA -, Candidate Countries and Switzerland

- others:

Serbia, Vatican City

These countries outside the EEA and Switzerland are affected by this FSCA:

Algeria, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Egypt, India, Indonesia, Israel, South Korea, Libya, Malaysia, Mexico, Morocco, New Zealand, Russian Federation, Singapore, South Africa, Thailand, Tunisia, United States of America, Vietnam

## 8 Comments

I affirm that the information given above is correct to the best of my knowledge.

*T. Mitchell*

*PP.*

\_\_\_\_\_  
Anthony Walsh  
Name

Frimley, Camberley 21st May 2012  
City Date

Submission of this report does not, in itself, represent a conclusion by the manufacturer and / or authorized representative or the National Competent Authority that the content of this report is complete or accurate, that the medical device(s) listed failed in any manner and/or that the medical device(s) caused or contributed to the alleged death or deterioration in the state of the health of any person.